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ABSTRACT
Objective To evaluate the relation between Parkinson’s
disease and prior use of non-steroidal anti-inflammatory
drugs (NSAIDs) in a large cohort of men.
Design Case-control analysis nested in the Physicians’
Health Study.
Participants 22007 male physicians aged 40–84 years
without indications for or contraindications to regular
NSAID use and free of Parkinson’s disease at baseline.
Cases and controls were matched by age alone or by age
andscoresforconfounders(comorbidityandindicatorsof
NSAID use). Up to five controls were matched to each of
616 cases by age and 565 cases by age and confounder
scores.
Setting United States.
MainoutcomemeasuresOddsofhavingbeenexposedto
priornon-aspirinNSAIDoraspirinusebyparticipantswith
Parkinson’s disease and by their controls in each case-
control set.
Results Participants who had ever used non-aspirin
NSAIDs had an increased risk of Parkinson’s disease
(oddsratio1.28(95%CI1.05to1.56)intheagematched
group but not in the group also matched on confounder
scores (odds ratio 1.17 (0.94 to 1.46)). There was an
increased risk of Parkinson’s disease in men who had 1–
2 years of regular non-aspirin NSAID use (odds ratio 1.35
(1.07 to 1.70)), a finding that remained significant after
matching for confounder scores as well (odds ratio 1.35
(1.05 to 1.75)). In contrast, the significant association of
use of non-aspirin NSAIDs for ≥5 years (odds ratio 1.48
(1.05 to 2.09)) in the age matched group was entirely
attenuated in the group also matched on confounder
scores (1.03 (0.70 to 1.53)). There was also a suggestion
thatmenwhoregularlyusedaspirinhadanincreasedrisk
of Parkinson’s disease. Positive associations between
non-aspirin NSAID or aspirin and risk of Parkinson’s
disease tended to disappear when analyses were limited
to drug use ≥5 years before the disease diagnosis.
ConclusionsThiscase-controlstudydidnotfindevidence
that NSAID use reduces Parkinson’s disease risk. The
positive associations observed between NSAID use and
Parkinson’s disease might have been due to confounding
by indication as the use was clustered in the few years
before disease diagnosis.
INTRODUCTION
The evidence that neuroinflammation contributes to
the pathogenesis of Parkinson’s disease is
compelling.
1 Microglial reaction
2 and upregulation of
inflammatory mediators
3 are evident in the brains of
patients with Parkinson’s disease, and a variety of
non-steroidal anti-inflammatory drugs (NSAIDS) pro-
vide neuroprotection in animal models.
4-6 Although
there is abundant epidemiological evidence of a pro-
tective role for NSAIDs in the development of Alzhei-
mer’s disease, there have been relatively few
observationalstudiesofNSAIDuseandtheriskofPar-
kinson’s disease. Most of these studies have found use
of non-aspirin NSAIDs to be associated with a
decreased risk of Parkinson’s disease,
7-15 but one
reportedanincreasedrisk.
16Aspirinusehasbeenasso-
ciated with a decreased risk of Parkinson’s disease in
threestudies,
101415andeithernoeffectorincreasedrisk
in three others.
81217 Information on the relation
between duration of NSAID use and risk of Parkin-
son’s disease is limited by the relatively short follow-
up of most studies.
Analysis of drug effects in non-randomised studies
requirescarefulconsiderationforthepotentialofcon-
founding. There are many chronic conditions asso-
ciated with NSAID use, and an imbalance in these
comorbidities between patients with Parkinson’sd i s -
ease and reference subjects may obscure the associa-
tion between Parkinson’s disease and NSAIDs.
Furthermore, Parkinson’s disease may cause pain
anddiscomfortyearsbeforeitsdiagnosis,
18-20creating
an association with NSAIDs based on symptoms of
the disease itself—a bias known as confounding by
indication.
We investigated the relation between use of aspirin
and non-aspirin NSAIDs and Parkinson’s disease in a
largecohortofmenwithdetailedprospectiveinforma-
tion on drug use and over 25 years of follow-up, with a
methodologicalstrategydesignedtoillustratetheinflu-
ence of confounding.
METHODS
ThePhysicians’HealthStudywasarandomisedtrialof
aspirin(325mgeveryotherday)andβcarotene(50mg
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vascular disease and cancer among 22071 US male
physicians. Detailed descriptions of the study design
and findings have been published.
2122 At study entry
in 1982, participants were between 40 and 84 years;
had no history of cardiovascular disease, cancer, or
other serious illness; and had no indication for or con-
traindication to aspirin or non-aspirin NSAIDs. All
participants were tolerant to a three month run-in
phase of aspirin treatment. Baseline information was
self reported and collected by a mailed questionnaire
that asked about risk factors for disease as well as life-
style variables. Ninety two per cent of the participants
identified their ethnicity as white. Participants were
sent follow-up questionnaires asking about study out-
comesandothermedicalinformation,twiceinthefirst
year and then yearly. The aspirin arm was discontin-
ued after an average of five years of follow-up because
of a 44% risk reduction in myocardial infarction in the
aspirin group.
21 Post-trial follow-up is ongoing.
23 We
used follow-up information to 4 March 2008 in our
analysis.
Ascertainment of Parkinson’s disease
Weidentifiedallparticipantswhoreportedanewdiag-
nosis of Parkinson’s disease on their annual survey
between 1982 and 2008. To evaluate the accuracy of
theselfreportingofParkinson’sdisease,weperformed
a validation study using the available medical records
of 73 participants who indicated a new diagnosis of
Parkinson’s disease.
24 In the Physicians’ Health
Study, medical records were obtained for each
reported study outcome (cardiac event, transient
ischaemicattack,stroke,cancer,pulmonaryembolism
or death). A physician (JAD) evaluated the medical
records of participants who reported Parkinson’s dis-
easebeforedevelopinganoutcomeevent.Therecords
were then reviewed independently by two physicians
with training in neurology (TK and GL).
The clinical diagnosis of Parkinson’s disease was
considered valid if record review revealed one or
more of
 Established diagnosis of Parkinson’s disease in
the medical record or Parkinson’s disease as
cause of death on the death certificate
 Current use of medication for Parkinson’s
disease such as dihydroxyphenylalanine (DOPA)
or a DOPA agonist
 Neurological examination with physical findings
consistent with parkinsonism (at least two of rest
tremor, rigidity, bradykinesia, and postural
instability) with no evidence of a secondary
cause of parkinsonism such as stroke, history of
encephalitis, brain tumour, or neuroleptic
treatment in the year before disease onset.
Patients who developed dementia or severe
dysautonomia within the first year of diagnosis
were not considered valid cases of Parkinson’s
disease
 Patient with a diagnosis of Parkinson’s disease
who was followed by a neurologist or a
movement disorders specialist.
Of the 73 patients with available medical records,
the self reported diagnosis of Parkinson’s disease was
found to be valid in 90% (66 patients). In 7% it was not
possibletoexcludeasecondarycauseofparkinsonism,
andinonly3%wasthediagnosisofParkinson’sdisease
incorrect.
Ascertainment of controls
Aparticipantwasconsidereda controlif hewasfreeof
selfreportedParkinson’sdiseaseatthetimeofthediag-
nosis of the case (index date) and remained free of the
disease for five years from the index date (to avoid the
possibilityofsubclinicaldisease).However,weconsid-
eredparticipantsacontroliftheydiedwithinfiveyears
of the index date from a cause other than Parkinson’s
disease to avoid bias. We used information from the
questionnaireclosesttotheindexdatetodefinecomor-
bidities and covariates for cases and controls. If this
questionnaire was missing, information was imputed
from prior questionnaires.
Tobetterunderstandtheinfluenceofcomorbidityin
our analysis, we created two case-controls sets. In the
first set, eligible controls were of the same age as the
case. In the second set, participants were matched by
age and by scores for confounding variables (compris-
ingamodifiedCharlsoncomorbidityscore,ascorefor
indicatorsof NSAIDuse, and a score for side effects of
NSAID use). Controls were selected from the study
population in this manner: (a) we matched each case
toallpotentialcontrolsbyageatbaseline,(b)thedateof
the case diagnosis of Parkinson’s disease was assigned
to each potential control as the index date, (c) the
comorbidity score and two NSAID scores were calcu-
latedfor each controlatthe time of the index date,and
(d) up to five matched controls were randomly chosen
from all potential controls with the same confounder
scores as the case.
Definition of confounder scores
Thecomorbidityscorewascalculatedusingamodified
version of the Charlson comorbidity index, a scoring
system for common comorbid conditions that is
weighted according to mortality risk.
25 As participants
in the Physicians’ Health Study were apparently
healthy at baseline, the score reflected total comorbid-
ities accumulated between study entry and the index
date. Myocardial infarction, stroke, and cancer were
study end points and were confirmed by medical
record review. Other conditions were self reported
by the study participants. The Charlson index cate-
gorises renal and liver disease as mild or as moderate
to severe. Because we could not determine disease
severity, we categorised all liver disease as mild and
all renal disease as moderate to severe, as has been
done in other modifications of the Charlson index.
26
Solid tumours that were localised at presentation
received a score of 2, while those that were metastatic
received a score of 6.
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by assigning one point for each of the following condi-
tions:migraine,frequentheadache(reported≥3times),
osteoarthritis, inflammatory arthritis, cerebrovascular
disease, and coronary artery disease. A score for
NSAIDsideeffectsorcontraindicationswascalculated
by assigning a point for each of the following condi-
tions: gastrointestinal bleeding, ulcer, and gastro-
intestinal symptoms (nausea, vomiting, dyspepsia,
dysphagia).
Assessment of NSAID use
Participants completed annual questionnaires asking
about compliance with the study medication (aspirin
and β carotene), outside use of aspirin, drugs contain-
ing aspirin or non-aspirin NSAIDs, and their possible
side effects. Non-study aspirin and NSAID use was
reported as the number of days of use in the preceding
12 months, and was categorised as 0, 1–14, 15–60, or
>60 days. Regular use of aspirin and other NSAIDs
was defined as >60 days’ use per year. We included
both study and non-study aspirin use in the definition
oftheaspirinvariable.Becausefewparticipantshadno
regular aspirin exposure, cumulative exposure to
aspirin was categorised as 0–4, 5–9, 10–14, or
≥15 years of regular use. As regular NSAID use was a
contraindication to study participation, few partici-
pants were regular users of non-aspirin NSAIDs for
the first five years of the trial. Cumulative non-aspirin
NSAIDusewascategorisedas0, 1–2, 3–4, or≥5years.
Statistical analysis
Usingconditionallogisticregression,wecalculatedthe
odds ratio and 95% confidence interval of prior
non-aspirin NSAID or aspirin use by participants
with Parkinson’s disease and by their controls in each
case-controlset.WedefinedNSAIDexposureinthree
ways: (a) ever versus never regular use for non-aspirin
Table 1 |Characteristics and selected comorbidities of Parkinson’s disease cases and matched controls among 22007
participants in the Physicians’ Health Study. Values are numbers (percentages) of patients unless stated otherwise
Patient characteristics
Matched by age Matched by age and confounder scores*
Cases (n=616) Controls (n=3080) Cases (n=565) Controls (n=2458)
Mean (range) age at randomisation to study (years) 59.10 (40.1–85.0) 59.08 (40.0–84.7) 58.57 (40.1–85.0) 58.55 (40.0–85.0)
Mean (range) confounder scores:
Charlson comorbidity score 1.52 (0–11) 1.33 (0–10) 1.29 (0–7) 1.29 (0–7)
Indications for NSAIDs 0.92 (0–5) 0.84 (0–6) 0.83 (0–4) 0.83 (0–4)
Side effects from NSAIDs 0.67 (0–3) 0.64 (0–3) 0.61 (0–3) 0.61 (0–3)
History of smoking:
Past 299 (49) 1550 (50) 269 (48) 1185 (48)
Current 15 (2.4) 127 (4.1) 14 (2.5) 102 (4.2)
Takes alcohol daily 221 (36) 1025 (33) 200 (35) 833 (34)
Rarely takes exercise† 272 (44) 1229 (40) 247 (44) 921 (37)
Body mass index:
25–29 241 (39) 1219 (40) 220 (39) 1001 (41)
≥30 39 (6.3) 203 (6.6) 37 (6.6) 151 (6.1)
History of comorbidities:
Arthritis 11 (1.8) 36 (1.2) 6 (1.1) 22 (0.9)
Migraine 73 (12) 370 (12) 60 (11) 237 (9.6)
Chronic headache 138 (22) 690 (22) 121 (21) 511 (21)
Coronary artery disease 29 (4.7) 127 (4.1) 22 (3.9) 108 (4.4)
Stroke 10 (1.6) 28 (0.9) 7 (1.2) 11 (0.45)
Cancer 102 (17) 430 (14) 76 (14) 291 (12)
Diabetes 8 (1.3) 40 (1.3) 5 (0.9) 16 (0.7)
Peptic ulcer 115 (19) 559 (18) 97 (17) 415 (17)
Gastrointestinal bleeding 106 (17) 464 (15) 80 (14) 252 (10)
Gastrointestinal symptoms 25 (4.1) 139 (4.5) 19 (3.4) 85 (3.5)
Congestive heart failure 36 (5.9) 118 (3.8) 24 (4.3) 59 (2.4)
Pulmonary vascular disease 40 (6.5) 168 (5.5) 32 (5.7) 107 (4.4)
Liver disease 82 (13) 321 (10) 68 (12) 250 (10)
Renal disease 7 (1.1) 26 (0.8) 4 (0.7) 20 (0.8)
Chronic pulmonary disease 55 (8.9) 325 (11) 48 (8.5) 212 (8.6)
Hemiplegia 1 (0.2) 0 1 (0.2) 0
Dementia 30 (4.9) 47 (1.5) 24 (4.3) 19 (0.8)
Randomised to aspirin 304 (49) 1532 (50) 283 (50) 1249 (51)
*Confounder scores=modified Charlson comorbidity score, score for indicators of NSAID use, and score for NSAID side effects.
†Exercise sufficiently vigorous to raise a sweat.
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intheyearbeforematching,and(c)yearsofregularuse.
To investigate the possibility of increased NSAID use
just before identification of Parkinson’s disease as the
result of symptoms from the undiagnosed disease, we
repeated the above analyses using information on
NSAID use from five years before the index date. All
analyseswereadjustedforthefollowingriskfactorsfor
Parkinson’s disease: smoking (never, past, current),
alcoholuse(daily,weekly,monthly),vigorousexercise
(sufficient to cause sweating) (ever, never), and body
mass index (<25, 25–<30, ≥30). These covariates
were updated during the study, and we used the infor-
mation closest to the matching date. We adjusted for
aspirin use when estimating the effects of non-aspirin
NSAIDs and vice versa. To evaluate potential effect
modification, we stratified the analyses of cumulative
NSAID use by mean age at identification of Parkin-
son’sdisease(<74years,≥74years)andsmokingstatus
(ever, never). We included interaction terms in the
model to test for significant effect modification.
RESULTS
Using information collected during 25 years of follow-
up, we matched 616 cases of Parkinson’s disease to
3080 controls by age, and 565 cases to 2458 controls
by age and the confounder scores. In the age matched
group, mean age at study entry was 59.1 years, and
mean age at identification of Parkinson’s disease was
73.8years(range47.5–93.9).TheparticipantswithPar-
kinson’s disease were less likely than controls to have
smokedand substantially lesslikely to be currentsmo-
kers at the time of matching (2.4% v 4.1%). In the age
matched group, cases had higher mean comorbidity
scores than controls (1.52 v 1.33). Table 1 shows the
characteristics of the cases and controls.
Use of non-aspirin NSAIDs
In the age matched cohort, those who ever regularly
used NSAIDs had a slightly increased risk of Parkin-
son’sdisease(oddsratio1.28(95%confidenceinterval
1.05to1.56))(seetable 2).Theoddsratiodecreasedto
1.17 (0.94 to 1.46) in the group matched for age and
confounder scores. When we excluded NSAID use
within five years of the matching date, the association
in the agematched group disappeared (oddsratio 1.18
(0.94 to 1.48)).
There was no clear association between NSAID use
in the year before diagnosisofParkinson’s diseaseand
risk of Parkinson’s disease (table 3). There was an
increased risk of Parkinson’s disease in men who had
regular NSAID use of 1–2 years’ duration (odds ratio
1.35(1.07to1.70))andof≥5years’duration(oddsratio
1.48(1.05to2.09))intheagematchedgroup,butinthe
group also matched for confounder scores the risk was
increasedonlyinthosewith1–2yearsofuse(oddsratio
1.35 (1.05 to 1.75)) (table 4). When we excluded
NSAID use within five years of the matching date,
the association was borderline in the age matched
group but no longer apparent in the group also
matched for confounder scores. There was no trend
towardsincreasedordecreasedriskofParkinson’sdis-
ease acrosscategoriesofincreasingdurationofregular
use.
Use of aspirin
There was a suggestion of an increased risk of Parkin-
son’sdiseaseinmenwhoreportedaspirinuseformore
than four years in the group matched for confounder
scores (odds ratio 1.33 (1.00 to 1.78)), but there was no
associationafterexcludingaspirinusewithinfiveyears
of the matching date (table 2). There was no associa-
tionbetweenParkinson’sdiseaseriskandaspirinusein
theyearbeforethediseasewasreported(table 3).Men
who reported regular aspirin use of 5–9 years had an
increased risk of Parkinson’s disease (odds ratio 1.38
(1.02 to1.87)), but the association was not significant
for longer durations of use and disappeared after
excludingaspirin use within five years of the matching
date (table 4).
Tests for effect modification
There was no significant effect modification by either
age or smoking status on the relation between Parkin-
son’sdiseaseandNSAIDoraspirinuse.Neitherasen-
sitivity analysis excluding those with known vascular
disease nor one excluding participants with indicators
ofchronicpain(headache,migraine,arthritis)changed
the results substantially.
Table 2 |Association between regular use of NSAIDs and risk of Parkinson’s disease in cases
and matched controls from the Physicians’ Health Study. Values are numbers (percentages)
of patients unless stated otherwise
Cases Controls
Odds ratio (95% CI)* by drug use
At index date 5 years prior†
Controls matched by age n= =616 n= =3080
Non-aspirin NSAID use:
Never 417 (68) 2230 (72) 1.00 1.00
Ever used 199 (32) 850 (28) 1.28 (1.05 to 1.56) 1.18(0.94to1.48),n=680
Missing data‡ 1.77(0.59to5.27),n=368
Aspirin use:
0–4 years 123 (20) 680 (22) 1.00 1.00
>4 years 493 (80) 2400 (78) 1.20 (0.93 to 1.56) 1.07 (0.84 to 1.36)
Controls matched by age
and confounder scores§ §
n= =565 n= =2458
Non-aspirin NSAID use:
Never 386 (68) 1788 (73) 1.00 1.00
Ever used 179 (32) 670 (27) 1.17 (0.94 to 1.46) 1.02(0.79to1.32),n=539
Missing data‡ 2.04(0.53to7.78),n=349
Aspirin use:
0–4 years 114 (20) 582 (24) 1.00 1.00
>4 years 451 (80) 1876 (76) 1.33 (1.00 to 1.78) 1.01 (0.77 to 1.33)
*Estimated by conditional logistic regression. Analyses were adjusted for the following variables at time of
matching: smoking (never, past, current), alcohol (daily, weekly, monthly), body mass index (<25, 25–<30, ≥30),
exercise to sweat (ever v never). We adjusted for aspirin use when estimating effects of non-aspirin NSAIDS and
vice versa.
†Excluding drug use within 5 years before the index date.
‡Individuals who did not have a variable for NSAID use at 5 years before the index date (they may not have
been enrolled in the study).
§Confounder scores=modified Charlson comorbidity score, score for indicators of NSAID use, and score for
NSAID side effects.
RESEARCH
page 4 of 8 BMJ | ONLINE FIRST | bmj.comDISCUSSION
Resultsfromthislargenestedcase-controlstudydonot
provide evidence that regular NSAID use decreases
the risk of Parkinson’s disease. This is despite careful
adjustmentfor comorbidconditions,which can have a
substantial influence on the analysis of drug effects in
elderly populations.
27 Non-aspirin NSAID use among
cases was clustered in the few years before diagnosis,
and positive associations between non-aspirin NSAID
or aspirinuse and Parkinson’s disease tended to disap-
pear with increasing lag time. These findings under-
score the complex relation between NSAID use and
Parkinson’s disease and suggest the presence of con-
founding by indication.
Comparison with other studies
A small number of studies provide evidence that
NSAID use may decrease risk of Parkinson’s disease.
In a pooled analysis of data from the Nurses’ Health
Study and Health Professional Follow-up Study, regu-
lar users of non-aspirin NSAIDs at baseline had a rela-
tive risk of 0.55 (95% confidence interval 0.32 to 0.96)
for Parkinson’s disease.
10 In another large prospective
cohort, ibuprofen use was associated with a lower risk
ofParkinson’sdisease(relativerisk0.65(0.48to0.89)),
whereas aspirin, acetaminophen, and other NSAIDs
hadnoassociation.
9Inonecase-controlstudy,alonger
duration of regular non-aspirin NSAID use (≥2 years)
was associated with a substantially decreased risk of
Parkinson’s disease (odds ratio 0.45 (0.26 to 0.74)).
14
Two case-control studies suggest that regular users of
aspirin have a lower risk of Parkinson’s disease,
1415
while two others suggest an increased risk.
812
Incontrast,we foundnoconvincingprotectiveasso-
ciationbetweenaspirinornon-aspirinNSAIDuseand
Parkinson’s disease. The Rotterdam Study, a popula-
tion based cohort in which Parkinson’s disease was
diagnosed by examination in person, also found an
increased risk of Parkinson’s disease among regular
users of NSAIDs in a prospective analysis, although
the finding was not statistically significant (relative
risk 1.50 (0.95 to 2.37)).
16 At least three large prospec-
tivecohortsfoundnoassociationbetweenbaselinereg-
ular use of aspirin and Parkinson’s disease risk,
910
although in two of the cohorts a suggestion of
decreased risk was seen in users of higher doses (≥2
tablets daily).
10
Insomewaysthe Physicians’HealthStudycohort is
uniquelysuitedtoinvestigatetheeffectsofNSAIDs.At
baseline, our participants were all tolerant to aspirin
and had no imbalance in comorbidities or indications
for or against aspirin or NSAID use. Using a matched
case-control design, we were able to control for the
confoundingeffectofindicationsforandcontraindica-
tions to NSAID use as they developed over time.
However, a number of important distinctions
between the Physicians’ Health Study and prior
cohorts must be considered. Firstly, our population
was older than other cohorts, with an average age of
74 years at diagnosis of Parkinson’s disease. The effect
of a specific exposure can be strongly modified by the
age at which the cohort begins. In addition, the health
conscious physicians in our study are exceptionally
long lived,
28 and 25% of our cases of Parkinson’s dis-
ease were diagnosed after age 80. The protective asso-
ciation of non-aspirin NSAIDs on Parkinson’s disease
may be stronger in younger patients or in those with
youngeronsetdisease.IfNSAIDsdodelaytheonsetof
Parkinson’sdisease,thismightincreaseitsincidencein
oldage.
29However,wehadnoevidenceofeffectmod-
ification by age in our data. Alternatively, younger
patients may have different indications for NSAID
use or a longer duration of use than older patients.
Secondly, it is possible that, because of the highly
selected nature of our cohort, we are missing a group
inwhichaprotectivebenefitofNSAIDsmightbeseen.
However, there is no plausible reason to believe that
the effect of NSAIDs on Parkinson’s disease differs in
the participants of the Physicians’ Health Study as
compared with other populations.
Finally, we were unable to separate the exposure to
non-aspirin NSAIDs into individual NSAID types,
such as ibuprofen (which may be particularly protec-
tive against Parkinson’s disease).
9 However, at least in
early years of the study, ibuprofen was the most com-
monly used non-aspirin NSAID on the US market.
30
Table 3 |Association between short term use of NSAIDs and
risk of Parkinson’s disease in cases and matched controls
from the Physicians’ Health Study
Daysofuseinprioryear
Odds ratio (95% CI)*
At index date 5 years prior†
Controls matched by age
Non-aspirin NSAID use:
None 1.00 1.00
1–14 0.84 (0.65 to 1.08) 1.11 (0.87 to 1.43)
15–60 0.87 (0.64 to 1.18) 1.15 (0.86 to 1.55)
>60 1.10 (0.81 to 1.50) 1.09 (0.76 to 1.55)
Aspirin use:
None 1.00 1.00
1–14 0.82 (0.56 to 1.18) 0.96 (0.66 to 1.41)
15–60 1.15 (0.76 to 1.76) 1.12 (0.71 to 1.78)
>60 0.92 (0.74 to 1.14) 0.93 (0.73 to 1.18)
Controls matched by age and confounder scores‡ ‡
Non-aspirin NSAID use:
None 1.00 1.00
1–14 0.82 (0.63 to 1.07) 1.05 (0.81 to 1.37)
15–60 0.71 (0.51 to 0.99) 1.05 (0.76 to 1.45)
>60 0.82 (0.59 to 1.14) 0.66 (0.44 to 1.00)
Aspirin use:
None 1.00 1.00
1–14 0.90 (0.60 to 1.34) 0.98 (0.64 to 1.48)
15–60 1.29 (0.81 to 2.05) 1.23 (0.75 to 2.02)
>60 0.99 (0.78 to 1.26) 0.98 (0.75 to 1.28)
*Estimated by conditional logistic regression. Analyses were adjusted for
the following variables at time of matching: smoking (never, past,
current), alcohol (daily, weekly, monthly), body mass index (<25, 25–<30,
≥30), exercise to sweat (ever v never). We adjusted for aspirin use when
estimating effects of non-aspirin NSAIDS and vice versa.
†Excluding drug use within 5 years before the index date.
‡Confounder scores=modified Charlson comorbidity score, score for
indicators of NSAID use, and score for NSAID side effects.
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of drug effects
Our findings show the difficulties inherent in the eva-
luationof drugeffectsin non-randomised studies.First
istheinfluenceofcomorbidityontherelationbetween
NSAID use and Parkinson’s disease. This is particu-
larly important in an elderly cohort such as ours. The
confounding created by imbalance in comorbidities
canbeseenineitherdirection.Thepositiveassociation
between ever use of NSAIDs and Parkinson’s disease
disappeared when controls were matched on comor-
bidity. While it is difficult to match on individual
comorbid conditions, we show that matching on a
score is a useful method of balancing comorbidities.
31
Another important source of potential bias in non-
randomised studies of drugs effects is confounding by
indication. We found a positive association between
ever use of NSAID and Parkinson’s disease in the age
matched group and between cumulative aspirin use
and Parkinson’s disease in the group also matched for
confounders. These associations tended to disappear
with increasing lag time, suggesting that NSAID and
aspirin use in cases was clustered in the few years
before the diagnosis of Parkinson’s disease.
PainiscommoninParkinson’sdiseaseandmaybea
primary or secondary symptom.
32 Primary sensory
symptoms originate in the peripheral or central ner-
vous system, while secondary pain may be caused by
conditions such as dystonia and muscle cramps. Sen-
sory symptoms may precede the diagnosis of Parkin-
son’s disease for several years, even before motor
symptoms develop.
1920 As we did not have the date of
symptomonset,itispossiblethatourpatientswithPar-
kinson’s disease experienced increased pain for a few
years before the diagnosis, explaining the increase in
NSAID use around this time.
Strengths and limitations of study
Our analysis has a number of strengths. Valid data on
NSAID use is difficult to obtain through retrospective
means or pharmacy databases, since many NSAIDs
may be obtained over the counter and are often used
periodically. Unlike other studies, we present data on
aspirin and non-aspirin NSAID use collected yearly
over 25 years. The physicians who participated in this
study(atrialofaspirinforpreventionofcardiovascular
disease and cancer) were particularly motivated to
report NSAID use accurately. Participants in the Phy-
sicians’ Health Study had no indication or contraindi-
cation for NSAID use at study entry. As we also have
detailed information about comorbid conditions dur-
ing follow-up, our study is particularly well suited to
address concerns about indication bias. Since profes-
sion and socioeconomic status are known to be asso-
ciated with the risk of Parkinson’s disease,
33 the fact
that all our participants were physicians should help
to reduce confounding. The long follow-up allowed
us to examine the effects of duration of treatment, an
advantage over other studies.
A particular strength of our study is the nested case-
controldesign,which allowed for matchingon comor-
bidities and indicators of chronic NSAID use. This
enabled us to evaluate potential confounding effects
in a more careful way than is possible in a cohort
design. In addition, this design also takes into account
potential effect modification by the matching factors
on the association between NSAID use and Parkin-
son’sdisease,afactoftenignoredinmultivariableana-
lysis of cohort studies.
34 To be sure that 1:5 matching
was adequate, we performed a bootstrap analysis
which provided similar results, reassuring us that our
findings are robust.
Our study also has limitations. Firstly, our diagnosis
of Parkinson’s disease was based on self reporting by
the participating physicians. However, the self
reported diagnosis of Parkinson’s disease is known to
be highly valid in a population of health
professionals.
17 In our study, direct validation of
morethan10%oftheselfreportedcasesofParkinson’s
disease diagnoses by means of medical records
revealed an accuracy of 90%, which is similar to that
foundinothervalidationstudiesofselfreportinginthe
Physicians’HealthStudy.
35Aswedidnothavethedate
Table 4 |Association between cumulative regular use of NSAIDs and risk of Parkinson’s
disease in cases and matched controls from the Physicians’ Health Study. Values are
numbers (percentages) of patients unless stated otherwise
Yearsofregulardruguse Cases Controls
Odds ratio (95% CI)* by drug use
At index date 5 years prior†
Controls matched by age n= =616 n= =3080
Non-aspirin NSAID use:
0 417 (68) 2232 (72) 1.00 1.00
1–2 121 (20) 492 (16) 1.35 (1.07 to 1.70) 1.30 (0.99 to 1.69)
3–4 29 (4.7) 174 (5.7) 0.91 (0.60 to 1.37) 0.74 (0.45 to 1.23)
≥5 49 (8.0) 182 (5.9) 1.48 (1.05 to 2.09) 1.31 (0.82 to 2.09)
Aspirin use:
0–4 124 (20.1) 693 (22.5) 1.00 1.00
5–9 173 (28.1) 836 (27.2) 1.22 (0.92 to 1.62) 1.05 (0.80 to 1.36)
10–14 154 (25.0) 730 (23.7) 1.26 (0.93 to 1.72) 1.28 (0.95 to 1.73)
≥15 165 (26.8) 821 (26.7) 1.21 (0.88 to 1.68) 1.05 (0.72 to 1.52)
Controls matched by age
and confounder scores‡ ‡
n= =565 n= =2458
Non-aspirin NSAID use:
0 386 (68) 1789 (73) 1.00 1.00
1–2 111 (20) 370 (15) 1.35 (1.05 to 1.75) 1.12 (0.84 to 1.50)
3–4 27 (4.8) 137 (5.6) 0.82 (0.52 to 1.29) 0.75 (0.42 to 1.36)
≥5 41 (7.3) 162 (6.6) 1.03 (0.70 to 1.53) 0.81 (0.46 to 1.43)
Aspirin use:
0–4 115 (20.35) 591 (24.0) 1.00 1.00
5–9 165 (29.2) 656 (26.7) 1.38 (1.02 to 1.87) 0.96 (0.72 to 1.28)
10–14 138 (24.4) 579 (23.6) 1.30 (0.93 to 1.84) 1.29 (0.92 to 1.80)
≥15 147 (26.0) 632 (25.7) 1.31 (0.92 to 1.86) 1.02 (0.68 to 1.52)
*Estimated by conditional logistic regression. Analyses were adjusted for the following variables at time of
matching: smoking (never, past, current), alcohol (daily, weekly, monthly), body mass index (<25, 25–<30, ≥30),
exercise to sweat (ever v never). We adjusted for aspirin use when estimating effects of non-aspirin NSAIDS and
vice versa.
†Excluding drug use within 5 years before the index date. In these analyses, we controlled for missing
observations using an indicator variable. For non-aspirin NSAID use, there were 369 individuals missing
information in the age matched group and 349 in the group matched by age and confounder scores. For aspirin
use, there were 368 missing in the age matched group and 349 in the group matched by age and confounder
scores.
‡Confounder scores=modified Charlson comorbidity score, score for indicators of NSAID use, and score for
NSAID side effects.
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havehadthediseaseformonthstoyearsbeforereport-
ing it. To address this, we excluded data for the five
years before the date of reporting the Parkinson’s dis-
ease diagnosis. Our cohort is homogeneous in a num-
ber of important respects, being composed of men of
thesameeducationallevelandprofessionwhoarepre-
dominantly white. Hence, generalisability to other
populations may be limited. The median age of onset
of Parkinson’s disease in our cohort is older than in
many other studies, and our results may not be applic-
abletopeoplewithearlyonsetdisease.However,early
onset Parkinson’s disease affects only a small portion
ofpatients.Weperformeda largeamountofsubgroup
analyses, which may increase the risk of chance find-
ings. Finally, despite our attempts to adjust for con-
founding, our results may be limited by the presence
of residual and unmeasurable confounding in this
observational study.
Implication for clinical practice
NSAIDs have been proposed as potential preventive
agents for Parkinson’s disease, based on laboratory
evidence as well as results from a few large observa-
tionalstudies.
36However,anumberofsubsequentstu-
dies, including ours, suggest no protective effect.
Considering the substantial potential side effects of
chronic NSAID use, the totality of available data is
not sufficient to recommend NSAIDs for prevention
of Parkinson’s disease.
Direction for future research
Because of the inconsistencies in studies evaluating
NSAIDs as neuroprotective agents, further studies
are warranted to prove or disprove this hypothesis.
Such studies should take standard indication, contra-
indication, and side effects of NSAIDs into account
and should carefully evaluate the timing between
NSAID use and disease onset.
Insummary,inthisprospectivecase-controlstudyof
USmalephysicians,wefoundnoevidenceofaprotec-
tiveassociationbetween regularuse of aspirinor other
NSAIDs and the risk of Parkinson’s disease. Our
results show complex associations, and the positive
associations we observed between NSAIDs and Par-
kinson’s disease may be due to confounding by
indication, as the NSAID use was clustered in the few
years before diagnosis.
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